Michael B. Feldman
Research Subjects
Research Interests
Michael B. Feldman has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Bruce S. Klein
University of Wisconsin-Madison
1 shared publication - Carole Ober
Department of Human Genetics, University of Chicago, Chicago, IL, USA
1 shared publication - Daniel J. Jackson
University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA
1 shared publication - Darin L. Wiesner
Departments of Pediatrics, University of Wisconsin-Madison, Madison, WI, USA
1 shared publication - Gregory C. Kujoth
Departments of Genetics and Medical Genetics, University of Wisconsin, Madison, WI 53706, USA
1 shared publication Heather Paleczny
Kymera Therapeutics, Inc., Watertown, United States
1 shared publication
Latest Publications
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA5913
KT-621, an oral STAT6 degrader, in patients with moderate to severe atopic dermatitis and comorbid asthma or allergic rhinitis: safety and evidence of clinical activity across type 2 inflammatory diseases in a phase 1b trial
Background: Asthma and allergic rhinitis are common comorbidities in patients with atopic dermatitis (AD), driven by Type 2 inflammation and IL-4/IL-13–STAT6 signaling. KT-621 is an oral, once-daily, small-molecule STAT6 degrader. In a Phase 1b, single-arm, open-label trial in patients with AD, KT-621 demonstrated deep STAT6 degradation in blood and skin, clinical activity, and favorable tolerability. Aims and objectives: To evaluate the impact of KT-621 on relevant biomarker and clinical endpoints in the subset of patients with AD and comorbid asthma or allergic rhinitis. Methods: Adults with moderate to severe AD (validated Investigator Global Assessment scale for Atopic Dermatitis ≥3; Eczema Area and Severity Index ≥16) and comorbid asthma or allergic rhinitis received oral KT-621 100 or 200 mg once daily for 28 days. Evaluations included FeNO; the Asthma Control Questionnaire [ACQ-5], Total Nasal Symptom Score [TNSS], Rhinoconjunctivitis Quality of Life Questionnaire [RQLQ]); and safety. Results: Among 22 patients with AD (KT-621 100 mg, n=10; 200 mg, n=12), 4 had comorbid asthma (mean baseline FeNO=49 ppb; ACQ-5=2.5) and 9 had allergic rhinitis (mean baseline TNSS=4.4 [n=7]; RQLQ=2.4 [n=6]). At Week 4, patients with asthma had a median FeNO reduction of 55.9% and a clinically meaningful reduction in ACQ-5 (mean 1.2 points). At Week 4, patients with allergic rhinitis had clinically meaningful mean reductions in TNSS and RQLQ of 0.9 and 0.8 points, respectively. No treatment-related, serious, or severe adverse events were reported. Conclusion: In patients with AD and comorbid asthma or allergic rhinitis, KT-621 showed improvements in FeNO and respiratory patient-reported outcomes, supporting potential efficacy across multiple Type 2 inflammatory diseases.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA5913
KT-621, an oral STAT6 degrader, in patients with moderate to severe atopic dermatitis and comorbid asthma or allergic rhinitis: safety and evidence of clinical activity across type 2 inflammatory diseases in a phase 1b trial
Background: Asthma and allergic rhinitis are common comorbidities in patients with atopic dermatitis (AD), driven by Type 2 inflammation and IL-4/IL-13–STAT6 signaling. KT-621 is an oral, once-daily, small-molecule STAT6 degrader. In a Phase 1b, single-arm, open-label trial in patients with AD, KT-621 demonstrated deep STAT6 degradation in blood and skin, clinical activity, and favorable tolerability. Aims and objectives: To evaluate the impact of KT-621 on relevant biomarker and clinical endpoints in the subset of patients with AD and comorbid asthma or allergic rhinitis. Methods: Adults with moderate to severe AD (validated Investigator Global Assessment scale for Atopic Dermatitis ≥3; Eczema Area and Severity Index ≥16) and comorbid asthma or allergic rhinitis received oral KT-621 100 or 200 mg once daily for 28 days. Evaluations included FeNO; the Asthma Control Questionnaire [ACQ-5], Total Nasal Symptom Score [TNSS], Rhinoconjunctivitis Quality of Life Questionnaire [RQLQ]); and safety. Results: Among 22 patients with AD (KT-621 100 mg, n=10; 200 mg, n=12), 4 had comorbid asthma (mean baseline FeNO=49 ppb; ACQ-5=2.5) and 9 had allergic rhinitis (mean baseline TNSS=4.4 [n=7]; RQLQ=2.4 [n=6]). At Week 4, patients with asthma had a median FeNO reduction of 55.9% and a clinically meaningful reduction in ACQ-5 (mean 1.2 points). At Week 4, patients with allergic rhinitis had clinically meaningful mean reductions in TNSS and RQLQ of 0.9 and 0.8 points, respectively. No treatment-related, serious, or severe adverse events were reported. Conclusion: In patients with AD and comorbid asthma or allergic rhinitis, KT-621 showed improvements in FeNO and respiratory patient-reported outcomes, supporting potential efficacy across multiple Type 2 inflammatory diseases.
- Open Access
Club cell TRPV4 as a damage sensor driving lung allergic inflammation
SUMMARY: Airway epithelium is the first body surface to contact inhaled irritants and report danger. We studied how epithelial cells recognize and respond to protease, which is a critical component of many allergens that provoke asthma. In a murine model, the aeroallergen alkaline protease 1 (Alp1) of Aspergillus sp. elicited helper T (Th) cell-dependent lung eosinophilia. Bronchiolar club cells responded rapidly to Alp1 by coordinating the accumulation of allergic immune cells in the lung. Alp1 degraded bronchiolar cell junctions, and club cells within the bronchioles propagated this signal via calcium and calcineurin to incite inflammation. In two human cohorts, we linked fungal sensitization and asthma with SNP/protein expression of the mechanosensitive calcium channel, TRPV4. TRPV4 was also necessary and sufficient for club cells to sensitize mice to Alp1. Thus, club cells detect junction damage as mechanical stress, which signals danger via TRPV4, calcium and calcineurin to initiate Th cell sensitization. Graphical
Open AccessClub cell TRPV4 as a damage sensor driving lung allergic inflammation
SUMMARY: Airway epithelium is the first body surface to contact inhaled irritants and report danger. We studied how epithelial cells recognize and respond to protease, which is a critical component of many allergens that provoke asthma. In a murine model, the aeroallergen alkaline protease 1 (Alp1) of Aspergillus sp. elicited helper T (Th) cell-dependent lung eosinophilia. Bronchiolar club cells responded rapidly to Alp1 by coordinating the accumulation of allergic immune cells in the lung. Alp1 degraded bronchiolar cell junctions, and club cells within the bronchioles propagated this signal via calcium and calcineurin to incite inflammation. In two human cohorts, we linked fungal sensitization and asthma with SNP/protein expression of the mechanosensitive calcium channel, TRPV4. TRPV4 was also necessary and sufficient for club cells to sensitize mice to Alp1. Thus, club cells detect junction damage as mechanical stress, which signals danger via TRPV4, calcium and calcineurin to initiate Th cell sensitization. Graphical